Biotech's Most Volatile Binary Events for Q1
Nothing provides greater stock price swings in the biotech sector than late-stage clinical trial results and drug approval decisions from the U.S. Food and Drug Administration. A recent research report from investment bank Jefferies (NYSE: JEF) listed key biotech events for the coming quarters, along with their potential upside and downside returns. Here we highlight four companies with market caps greater than $1 billion that could have the largest potential swings in stock price, according to the report.
Image Source: Getty Images
Esperion Therapeutics (NASDAQ: ESPR) leads off with two important FDA approval deadlines slated near the end of February. At stake is the fate of its drug bempedoic acid, a treatment for lowering low-density lipoprotein cholesterol (LDL-C).
Source Fool.com
